Found: 83
Select item for more details and to access through your institution.
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
- Published in:
- 2002
- By:
- Publication type:
- journal article
The Influence of Levodopa and the COMT Inhibitor on Serum Vitamin B12 and Folate Levels in Parkinson’s Disease Patients.
- Published in:
- European Neurology, 2007, v. 58, n. 2, p. 96, doi. 10.1159/000103644
- By:
- Publication type:
- Article
Switch-Over from Tolcapone to Entacapone in Severe Parkinson’s Disease Patients.
- Published in:
- European Neurology, 2001, v. 46, n. 1, p. 11, doi. 10.1159/000050749
- By:
- Publication type:
- Article
Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study.
- Published in:
- European Neurology, 2001, v. 45, n. 2, p. 111, doi. 10.1159/000052104
- By:
- Publication type:
- Article
Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone.
- Published in:
- Neurology India, 2017, v. 65, n. 4, p. 746, doi. 10.4103/neuroindia.NI_597_16
- By:
- Publication type:
- Article
Rasagiline.
- Published in:
- Drugs & Aging, 2005, v. 22, n. 1, p. 83, doi. 10.2165/00002512-200522010-00006
- By:
- Publication type:
- Article
Comparative Tolerability of the Newer Generation Antiparkinsonian Agents.
- Published in:
- Drugs & Aging, 2000, v. 16, n. 1, p. 55, doi. 10.2165/00002512-200016010-00005
- By:
- Publication type:
- Article
Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1.
- Published in:
- Science Translational Medicine, 2019, v. 11, n. 488, p. N.PAG, doi. 10.1126/scitranslmed.aau7116
- By:
- Publication type:
- Article
The Liver Toxicity Biomarker Study Phase I: Markers for the Effects of Tolcapone or Entacapone.
- Published in:
- Toxicologic Pathology, 2012, v. 40, n. 6, p. 951, doi. 10.1177/0192623312444026
- By:
- Publication type:
- Article
Analytical Methods for Determination of Entacapone in Pharmaceuticals and Urine.
- Published in:
- Eurasian Journal of Analytical Chemistry, 2015, v. 10, n. 3, p. 150
- By:
- Publication type:
- Article
Thermal behavior of entacapone, a catechol-O-methyltransferase inhibitor used in Parkinson’s disease.
- Published in:
- Journal of Thermal Analysis & Calorimetry, 2018, v. 134, n. 1, p. 711, doi. 10.1007/s10973-018-7097-y
- By:
- Publication type:
- Article
Thermal decomposition kinetics of the antiparkinson drug 'entacapone' under isothermal and non-isothermal conditions.
- Published in:
- Journal of Thermal Analysis & Calorimetry, 2017, v. 130, n. 3, p. 2359, doi. 10.1007/s10973-017-6664-y
- By:
- Publication type:
- Article
A Brazilian Football Player Still on the Pitch After 10 Years of Parkinson's Disease with Severe Freezing of Gait.
- Published in:
- Movement Disorders Clinical Practice, 2015, v. 2, n. 1, p. 43, doi. 10.1002/mdc3.12110
- By:
- Publication type:
- Article
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
- Published in:
- Neuroscience & Behavioral Physiology, 2008, v. 38, n. 9, p. 933, doi. 10.1007/s11055-008-9085-3
- By:
- Publication type:
- Article
A Novel Approach using Hydrotropic Solubalization Technique for Quantitative Estimation of Entacapone in Bulk Drug and Dosage Form.
- Published in:
- Advanced Pharmaceutical Bulletin, 2013, v. 3, n. 2, p. 409, doi. 10.5681/apb.2013.065
- By:
- Publication type:
- Article
Unsuitability of pharmacopoeial dissolution conditions for entacapone: Effects of various dissolution parameters on dissolution profile.
- Published in:
- Journal of Pharmaceutical Negative Results, 2012, v. 3, n. 1, p. 49, doi. 10.4103/0976-9234.99667
- By:
- Publication type:
- Article
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
- Published in:
- European Journal of Neurology, 2004, v. 11, n. 9, p. 593, doi. 10.1111/j.1468-1331.2004.00860.x
- By:
- Publication type:
- Article
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
- Published in:
- European Journal of Neurology, 2003, v. 10, n. 2, p. 137, doi. 10.1046/j.1468-1331.2003.00559.x
- By:
- Publication type:
- Article
Twelve-month safety of entacapone in patients with Parkinson’s disease.
- Published in:
- European Journal of Neurology, 2001, v. 8, n. 1, p. 53, doi. 10.1046/j.1468-1331.2001.00168.x
- By:
- Publication type:
- Article
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol- O-methyltransferase inhibition.
- Published in:
- Journal of Neural Transmission, 2014, v. 121, n. 11, p. 1357, doi. 10.1007/s00702-014-1213-3
- By:
- Publication type:
- Article
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
- Published in:
- European Journal of Clinical Pharmacology, 2009, v. 65, n. 5, p. 443, doi. 10.1007/s00228-009-0622-y
- By:
- Publication type:
- Article
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man: A study using a stable isotope technique.
- Published in:
- European Journal of Clinical Pharmacology, 2001, v. 56, n. 11, p. 821, doi. 10.1007/s002280000244
- By:
- Publication type:
- Article
Entacapone promotes cAMP-dependent colonic Cl.
- Published in:
- Neurogastroenterology & Motility, 2011, v. 23, n. 7, p. 657, doi. 10.1111/j.1365-2982.2011.01715.x
- By:
- Publication type:
- Article
Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi- Drug and Extensively Drug Resistant Tuberculosis.
- Published in:
- PLoS Computational Biology, 2009, v. 5, n. 7, p. 1, doi. 10.1371/journal.pcbi.1000423
- By:
- Publication type:
- Article
Study of Relative Association, Apparent Molar Compressibility and Free Length of Entacapone API in alcohols at different Frequencies.
- Published in:
- Indian Journal of Pharmaceutical Education & Research, 2016, v. 50, n. 4, p. 703, doi. 10.5530/ijper.50.4.23
- By:
- Publication type:
- Article
Dissolution Rate Enhancement of Entacapone and Formulation of its Oro-Dispersible Tablets: Applying Statistical Design.
- Published in:
- Indian Journal of Pharmaceutical Education & Research, 2016, v. 50, n. 4, p. 549, doi. 10.5530/ijper.50.4.7
- By:
- Publication type:
- Article
Effect of entacapone on plasma homocysteine levels in Parkinson’s disease patients.
- Published in:
- Neurological Sciences, 2010, v. 31, n. 5, p. 565, doi. 10.1007/s10072-010-0262-0
- By:
- Publication type:
- Article
Clinical experience of tolcapone in advanced Parkinson’s disease.
- Published in:
- Neurological Sciences, 2008, v. 29, p. 380, doi. 10.1007/s10072-008-1052-9
- By:
- Publication type:
- Article
Parkinson Treatment Approval.
- Published in:
- JAMA: Journal of the American Medical Association, 1999, v. 282, n. 21, p. 1995, doi. 10.1001/jama.282.21.1995-JFD90010-3-1
- By:
- Publication type:
- Article
Stability-indicating method of entacapone-related substances using UPLC in finished dosage form.
- Published in:
- Current Science (00113891), 2018, v. 114, n. 3, p. 644, doi. 10.18520/cs/v114/i03/644-649
- By:
- Publication type:
- Article
Entacapone augmentation of antipsychotic treatment in schizophrenic patients with negative symptoms; a double-blind placebo-controlled study.
- Published in:
- International Journal of Neuropsychopharmacology, 2014, v. 17, n. 2, p. 337, doi. 10.1017/S1461145713001387
- By:
- Publication type:
- Article
Synergistic inhibition of lung cancer cell lines by (−)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
- Published in:
- Carcinogenesis, 2014, v. 35, n. 2, p. 365, doi. 10.1093/carcin/bgt347
- By:
- Publication type:
- Article
Entacapone/Levodopa/Carbidopa Combination Tablet.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 5, p. 310, doi. 10.2165/00126839-200304050-00006
- Publication type:
- Article
AAN Releases Recommendations on Treatment of Parkinson's Disease.
- Published in:
- American Family Physician, 2007, v. 75, n. 6, p. 922
- By:
- Publication type:
- Article
Levodopa/carbidopa/entacapone versus levodopa/ dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, metaanalysis, and economic evaluation.
- Published in:
- Therapeutics & Clinical Risk Management, 2018, v. 14, p. 709, doi. 10.2147/TCRM.S163190
- By:
- Publication type:
- Article
Pooled analysis of phase III with entacapone in Parkinson's disease.
- Published in:
- Acta Neurologica Scandinavica, 2014, v. 130, n. 4, p. 239, doi. 10.1111/ane.12278
- By:
- Publication type:
- Article
Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
- Published in:
- Acta Neurologica Scandinavica, 2013, v. 127, n. 2, p. 124, doi. 10.1111/j.1600-0404.2012.01700.x
- By:
- Publication type:
- Article
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
- Published in:
- Acta Neurologica Scandinavica, 2005, v. 111, n. 1, p. 21, doi. 10.1111/j.1600-0404.2004.00363.x
- By:
- Publication type:
- Article
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
- Published in:
- Acta Neurologica Scandinavica, 2002, v. 105, n. 4, p. 245, doi. 10.1034/j.1600-0404.2002.1o174.x
- By:
- Publication type:
- Article
Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson’s Disease with Motor Fluctuation: A Systematic Meta-Analysis.
- Published in:
- European Neurology, 2017, v. 78, n. 3/4, p. 143, doi. 10.1159/000479555
- By:
- Publication type:
- Article
Is There a Difference between Levodopa/ Dopa-Decarboxylase Inhibitor and Entacapone and Levodopa/Dopa-Decarboxylase Inhibitor Dose Fractionation Strategies in Parkinson’s Disease Patients Experiencing Symptom Re-Emergence due to Wearing-Off?
- Published in:
- European Neurology, 2009, v. 61, n. 2, p. 69, doi. 10.1159/000177938
- By:
- Publication type:
- Article
Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Knee Lichenification In Parkinson's Disease: "Parkinson Knees".
- Published in:
- Medicine & Health Rhode Island, 2009, v. 92, n. 12, p. 415
- By:
- Publication type:
- Article
The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.
- Published in:
- Neurological Sciences, 2003, v. 24, n. 3, p. 197, doi. 10.1007/s10072-003-0128-9
- By:
- Publication type:
- Article
Entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose.
- Published in:
- British Journal of Clinical Pharmacology, 2002, v. 54, n. 4, p. 363, doi. 10.1046/j.1365-2125.2002.01654.x
- By:
- Publication type:
- Article
Effect of the catechol-O -methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.
- Published in:
- British Journal of Clinical Pharmacology, 2002, v. 53, n. 5, p. 485, doi. 10.1046/j.1365-2125.2002.01587.x
- By:
- Publication type:
- Article
Levodopa-carbidopa-entacapone overdose presenting as altered mental status, xanthoderma, and yellowish sclera.
- Published in:
- Signa Vitae, 2018, v. 14, n. 2, p. 75, doi. 10.22514/SV142.102018.12
- By:
- Publication type:
- Article
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
- Published in:
- Journal of Neural Transmission, 2009, v. 116, n. 10, p. 1253, doi. 10.1007/s00702-009-0275-0
- By:
- Publication type:
- Article
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson’s disease.
- Published in:
- Journal of Neural Transmission, 2008, v. 115, n. 6, p. 843, doi. 10.1007/s00702-008-0025-8
- By:
- Publication type:
- Article
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease.
- Published in:
- Journal of Neural Transmission, 2006, v. 113, n. 10, p. 1441, doi. 10.1007/s00702-006-0442-5
- By:
- Publication type:
- Article